Scynexis Inc (SCYX)vsViatris Inc (VTRS)
SCYX
Scynexis Inc
$0.88
-2.13%
HEALTHCARE · Cap: $39.10M
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 69314% more annual revenue ($14.30B vs $20.60M). VTRS leads profitability with a -24.6% profit margin vs -41.8%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
SCYX
Hold50
out of 100
Grade: D+
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 56.4%
18.1% revenue growth
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -16.5% — below average capital efficiency
Currently unprofitable
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : SCYX
The strongest argument for SCYX centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : SCYX
The primary concerns for SCYX are EPS Growth, Market Cap, Return on Equity.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
SCYX profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
SCYX carries more volatility with a beta of 1.32 — expect wider price swings.
SCYX is growing revenue faster at 18.1% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
SCYX scores higher overall (50/100 vs 50/100) and 18.1% revenue growth. Both earn "Hold" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Scynexis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?